Vocal patient advocates are increasingly distorting public health priorities, research agendas, and even public policy. Media and policy makers, as sympathetic to the voices of patients and family members as the rest of us, are giving the advocates influence that outweighs their credentials.
President Obama has been on an "innovation" binge these days. Since the start of the year -- when he mentioned "innovation" nine times in the State of the Union -- the President has celebrated "Innovation Week" and released a 76-page " Strategy For American Innovation."
The agency that runs the Medicare program decided in late March that it will pay for patients to receive an advanced new treatment for prostate cancer called Provenge.
Everyone who's ever been on the lookout for a good deal knows that price is one thing, but value is another. Cheaper isn't always better; some things that cost more are worth it.
The United States is the world’s leader in pharmaceutical innovation, especially in the newest form of drugs created through biomedical research.
Health care debates often focus on budget numbers or policy goals. Seldom do we hear how policy changes will affect actual patients. Take what the Food and Drug Administration (FDA) is doing with the late-stage cancer drug Avastin.
The Food and Drug Administration is preparing to deny late-stage breast cancer patients access to the critical, but expensive, life-extending drug Avastin.
The egg that is the president’s health care reform legislation is starting to crack.
Last week, the National Football League called off an NFL game because it was going to snow in Philadelphia. This has not happened before. American football is played under all weather conditions.
The battle over health care took a turn for the better this week, but, unfortunately, things could take a turn for the worse for breast cancer patients by Friday.